Overview
Acute diastolic heart failure (ADHF) represents a critical clinical syndrome characterized by impaired ventricular relaxation and filling despite normal or near-normal systolic function. This condition often complicates underlying cardiac diseases such as ischemic heart disease, hypertension, and cardiomyopathies. The pathophysiology of ADHF involves complex neurohumoral interactions that affect myocardial stiffness and compliance, leading to symptoms of dyspnea, fatigue, and fluid retention. Early recognition and targeted management are crucial for improving outcomes in these patients. Understanding the specific mechanisms and diagnostic markers can significantly enhance clinical decision-making and patient care.
Pathophysiology
The pathophysiology of acute diastolic heart failure (ADHF) involves intricate neurohumoral modulation, with urotensin-II (U-II) playing a pivotal role. U-II concentration-dependently decreases inotropy and increases resting muscle length, thereby reducing muscle stiffness [PMID:17701026]. This effect is mediated through the activation of the urotensin-II receptor, which subsequently influences downstream pathways involving nitric oxide (NO) and prostaglandins. These mediators collectively contribute to alterations in myocardial compliance and relaxation, critical factors in the development of diastolic dysfunction. The involvement of NO and prostaglandins suggests a multifaceted regulatory mechanism that could be targeted therapeutically to mitigate the adverse effects on diastolic function. Understanding these pathways highlights the potential for novel therapeutic interventions aimed at restoring normal myocardial stiffness and improving diastolic performance.
Clinical Presentation
Patients with acute diastolic heart failure (ADHF) often present with a constellation of symptoms reflecting impaired ventricular filling. Common clinical manifestations include dyspnea, particularly on exertion, orthopnea, and paroxysmal nocturnal dyspnea. These symptoms arise due to the heart's inability to adequately fill during diastole, leading to pulmonary congestion and systemic venous congestion. A specific and measurable clinical marker observed in certain contexts, such as acute cardiac allograft rejection, is the prolongation of the Te interval—defined as the time from maximal posterior wall contraction to peak end-diastolic velocity [PMID:1468819]. This interval significantly extends during episodes of rejection, correlating strongly with histopathological findings from myocardial biopsies. In clinical practice, monitoring such parameters can aid in early detection and management of ADHF, especially in transplant recipients where rejection poses a significant risk.
Diagnosis
Diagnosing acute diastolic heart failure (ADHF) requires a multifaceted approach incorporating clinical assessment, imaging, and biomarker evaluation. Traditional diagnostic tools like echocardiography are fundamental, providing insights into ventricular function, diastolic pressures, and structural changes. However, recent studies have highlighted the utility of novel biomarkers in enhancing diagnostic accuracy. FILDARIA, a biomarker studied in a cohort of 235 patients, demonstrated markedly elevated levels in acute heart failure (AHF) patients compared to those with non-cardiac dyspnea (NCD) [PMID:40877033]. FILDARIA showed a diagnostic accuracy of 99.4%, comparable to brain natriuretic peptide (BNP), and can be rapidly assessed using lateral flow assays, potentially streamlining point-of-care diagnostics. This rapid and accurate measurement could significantly improve the speed and accessibility of ADHF diagnosis, particularly in settings where timely intervention is critical. Additionally, the prolongation of the Te interval, as noted in patients experiencing acute rejection [PMID:1468819], serves as a valuable adjunct in clinical settings where rejection is a concern, correlating well with invasive diagnostic measures like myocardial biopsies.
Management
The management of acute diastolic heart failure (ADHF) focuses on alleviating symptoms, improving cardiac function, and addressing underlying causes. Therapeutic strategies often include pharmacological interventions aimed at modulating the neurohumoral pathways implicated in diastolic dysfunction. Evidence from studies indicates that urotensin-II (U-II) plays a detrimental role through its effects on myocardial stiffness [PMID:17701026]. The use of U-II receptor antagonists, such as urantide, along with inhibitors of nitric oxide synthase and cyclooxygenase, can effectively abolish the adverse effects of U-II on myocardial stiffness. These interventions suggest potential therapeutic targets for enhancing diastolic function. In clinical practice, optimizing diuretic therapy to manage fluid overload, adjusting afterload with vasodilators, and managing comorbidities like hypertension and coronary artery disease are essential components of management. Furthermore, monitoring parameters such as the Te interval can provide valuable feedback on the efficacy of treatment, as evidenced by its normalization following successful intervention in rejection scenarios [PMID:1468819]. Tailored approaches that integrate these pharmacological and monitoring strategies can significantly improve patient outcomes in ADHF.
Key Recommendations
References
1 Rouet K, Rouet P, Koukoui F, Galinier M. Diagnostic accuracy and rapid testing of a novel acute heart failure biomarker: A laboratory evaluation and comparison with natriuretic peptides. Annals of clinical biochemistry 2026. link 2 Fontes-Sousa AP, Brás-Silva C, Pires AL, Monteiro-Sousa D, Leite-Moreira AF. Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling. Naunyn-Schmiedeberg's archives of pharmacology 2007. link 3 Park JW, Warnecke H, Deng M, Schüler S, Heinrich KW, Hetzer R. Early diastolic left ventricular function as a marker of acute cardiac rejection: a prospective serial echocardiographic study. International journal of cardiology 1992. link90266-6)